Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck

What is the purpose of this trial?

This is a single arm Phase II study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with an immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.



Yale Cancer Center

Start Date: 04/03/2017

End Date: 12/30/2019

Last Updated: 07/10/2019

Study HIC#: 1608018260

Get Involved

For more information about this study, contact:
Elzbieta Nowacki
+1 203-737-7981
elzbieta.nowacki@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image